Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.

ABSTRACT:

Background

The current literature indicates that a considerable number of patients in ovarian carcinoma clinical trials have histopathological diagnoses in conflict with inclusion criteria. It has been suggested that specialised pathology review prior to randomisation should become the standard procedure in study protocols. We hypothesised that our new, internet-based high-throughput infrastructure would be capable of providing specialised pathology review within 10 working days (w.d.).

Methods

Patients scheduled for the AGO OVAR17 ovarian carcinoma chemotherapy trial were registered for expert pathologic case review using a new internet-based central pathology review platform prior to randomisation. All original slides were requested from local pathologists. Slides were sca

SUBMITTER: Kommoss S 

PROVIDER: S-EPMC5294479 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature